🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Luis Paz‐Ares

Hospital Universitario 12 De Octubre

ORCID: 0000-0002-1947-3364
Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 2%percentile
2.8Author DataRank

Indexed papers

2in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 2 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Top data-sharing exemplar

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium

British Journal of Cancer(2020)10.1038/s41416-020-0900-0
Top 10%
2.1DataRank
Top 10%68 citations

Dominique‐Laurent Couturier, Anna Paterson, Anthony N. Karnezis, Christine Chow, Tayyebeh M. Nazeran +92 more

Papers

Driven by 14 papers — median percentile 81. Top paper: “Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer”.

Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

Journal of Clinical Oncology(2022)10.1200/jco.21.01308
N/A
7.3DataRank · unranked
1324 citations

Corinne Faivre‐Finn, Jhanelle E. Gray, David Vicente, David Planchard, Luis Paz‐Ares +20 more

Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC—an Update From the PACIFIC Trial

Journal of Thoracic Oncology(2021)10.1016/j.jtho.2020.12.015
N/A
6.9DataRank · unranked
471 citations

David Vicente, Takayasu Kurata, David Planchard, Luis Paz‐Ares, Johan Vansteenkiste +18 more

Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study

The Lancet Oncology(2021)10.1016/s1470-2045(21)00247-3
N/A
5.0DataRank · unranked
445 citations

Giuseppe Curigliano, Dong‐Wan Kim, Ki Hyeong Lee, Benjamin Besse, Christina S. Baik +20 more

Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial

Nature Medicine(2022)10.1038/s41591-022-01931-y
N/A
3.9DataRank · unranked
240 citations

Philippe A. Cassier, Salvatore Siena, Elena Garralda, Luis Paz‐Ares, Pilar Garrido +14 more

Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial

The Lancet Oncology(2024)10.1016/s1470-2045(24)00064-0
N/A
3.7DataRank · unranked
164 citations

Enriqueta Felip, Dipesh Uprety, Misako Nagasaka, Kazuhiko Nakagawa, Luis Paz‐Ares +15 more

Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium

British Journal of Cancer(2020)10.1038/s41416-020-0900-0
Top 10%
2.1DataRank
Top 10%68 citations

Dominique‐Laurent Couturier, Anna Paterson, Anthony N. Karnezis, Christine Chow, Tayyebeh M. Nazeran +92 more

Molecular classification and biomarkers of outcome with immunotherapy in extensive-stage small-cell lung cancer: analyses of the CASPIAN phase 3 study

Molecular Cancer(2024)10.1186/s12943-024-02014-x
N/A
0.975DataRank · unranked
43 citations

Miljenka Vuko, Jaime Rodriguez‐Canales, Johannes Zimmermann, Markus Schick, Cathy O’Brien +13 more

p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study

The Journal of Pathology Clinical Research(2023)10.1002/cjp2.311
Top 27%
0.751DataRank
Top 27%28 citations

Eunyoung Kang, Ashley Weir, Peter Rambau, Cheng‐Han Lee, Gregg Nelson +95 more

Increased FOXJ1 protein expression is associated with improved overall survival in high-grade serous ovarian carcinoma: an Ovarian Tumor Tissue Analysis Consortium Study

British Journal of Cancer(2022)10.1038/s41416-022-02014-y
N/A
0.312DataRank · unranked
7 citations

Eunyoung Kang, Nicola S. Meagher, Gregg Nelson, Prafull Ghatage, Cheng‐Han Lee +88 more

1314P Patient-reported outcomes (PROs) from the phase III EVOKE-01 trial of sacituzumab govitecan (SG) vs docetaxel (doc) in metastatic non-small cell lung cancer (mNSCLC)

Annals of Oncology(2024)10.1016/j.annonc.2024.08.1371
N/A
0DataRank · unranked
2 citations

Luis Paz‐Ares, M.C. Garassino, Shobhit Baijal, J. Bennouna, D.B. Daniel +12 more

Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial

Journal of Thoracic Oncology(2020)10.1016/j.jtho.2020.03.003
N/A
0DataRank · unranked
222 citations

Tae Min Kim, David Vicente, Enriqueta Felip, Dae Ho Lee, Ki Hyeong Lee +10 more

Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non–small cell lung cancer without tumor PD‐L1 expression: A pooled analysis of 3 randomized controlled trials

Cancer(2020)10.1002/cncr.33142
N/A
0DataRank · unranked
111 citations

Corey J. Langer, Luis Paz‐Ares, Delvys Rodríguez‐Abreu, Balázs Halmos, Marina Chiara Garassino +8 more

Safety and efficacy of pralsetinib in RET fusion–positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial

Annals of Oncology(2022)10.1016/j.annonc.2022.08.002
N/A
0DataRank · unranked
181 citations

Giuseppe Curigliano, Michael Thomas, Vivek Subbiah, Christina S. Baik, Daniel S.W. Tan +21 more

IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy

Journal of Thoracic Oncology(2020)10.1016/j.jtho.2020.01.005
N/A
0DataRank · unranked
460 citations

Sanja Đačić, Ignacio I. Wistuba, Lynette M. Sholl, Prasad S. Adusumilli, Lukas Bubendorf +38 more